Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2009 | 09-2009 | 06-2009 | 03-2009 | 12-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,745,838 | 4,207,109 | 2,726,742 | 1,438,637 | 4,880,719 |
| Depreciation Amortization | 2,089,510 | 1,542,157 | 1,001,443 | 464,045 | 1,838,829 |
| Accounts receivable | -387,749 | 510,249 | 427,257 | 375,665 | -948,314 |
| Other Working Capital | -341,382 | 423,998 | 146,647 | 176,961 | -39,686 |
| Other Operating Activity | 168,943 | -1,240,970 | -1,889,570 | -1,756,590 | 1,263,072 |
| Operating Cash Flow | $7,275,160 | $5,442,543 | $2,412,519 | $698,718 | $6,994,620 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -2,895,691 | -1,717,733 | 138,962 | N/A |
| PPE Investments | -1,089,048 | -843,601 | -514,891 | -252,151 | -1,287,724 |
| Net Acquisitions | -2,370,630 | -1,518,903 | -1,509,391 | -1,492,059 | -250,000 |
| Purchase Of Investment | -248,970 | N/A | N/A | N/A | -923,937 |
| Sale Of Investment | 16,306 | N/A | N/A | N/A | 449,231 |
| Other Investing Activity | -6,368 | -3,392 | -1,135 | -510 | -75,061 |
| Investing Cash Flow | $-3,698,710 | $-5,261,587 | $-3,743,150 | $-1,605,758 | $-2,087,491 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,217,331 | 2,281,073 | 2,547,425 | 1,770,418 | -324,739 |
| Debt Issued | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | N/A |
| Debt Repayment | -2,483,176 | -2,483,176 | -2,483,176 | -1,983,176 | -913,948 |
| Common Stock Issued | 508,669 | 321,819 | 292,819 | 279,394 | 1,008,843 |
| Common Stock Repurchased | -826,345 | -825,386 | -824,781 | -822,953 | -1,081,806 |
| Dividend Paid | -2,414,460 | -1,795,684 | -1,177,308 | -559,081 | -2,174,252 |
| Financing Cash Flow | $1,002,019 | $498,646 | $1,354,979 | $1,684,602 | $-3,485,902 |
| Exchange Rate Effect | 118,848 | 84,291 | 67,934 | -14,789 | -115,160 |
| Beginning Cash Position | 4,112,022 | 4,112,022 | 4,112,022 | 4,112,022 | 2,456,384 |
| End Cash Position | 8,809,339 | 4,875,915 | 4,204,304 | 4,874,795 | 4,112,022 |
| Net Cash Flow | $4,697,317 | $763,893 | $92,282 | $762,773 | $1,655,638 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,275,160 | 5,442,543 | 2,412,519 | 698,718 | 6,994,620 |
| Capital Expenditure | -1,089,048 | -843,601 | -514,891 | -252,151 | -1,287,724 |
| Free Cash Flow | 6,186,112 | 4,598,942 | 1,897,628 | 446,567 | 5,706,896 |